A GHRP-6 study finds fewer bacteria in infected fish

The tilapia study connected GHRP-6 with a lower amount of bacteria inside infected fish, rather than only changes in laboratory measures of immunity. Researchers tested an oral, oil-based formulation in young tilapia, including fish exposed to Pseudomonas aeruginosa, the bacterium used to cause infection in the experiment, and fish not exposed to it. They assessed growth, bacterial levels, immune-related gene activity, and the activity of digestive enzymes, proteins that help break down food. MDPI

The fish receiving GHRP-6 gained more weight and length, and bacterial levels were lower after infection. Researchers also found changes in immune-related gene activity, meaning how actively cells used genetic instructions involved in immune responses. Those changes appeared across several tissues, including organs involved in breathing and digestion. MDPI

The digestive findings add another part to the study: GHRP-6 changed the activity of specific enzymes in the gut following the bacterial challenge. That connects the experiment's growth and infection questions with what was happening during digestion. The limitation is that these measurements do not establish whether the same effects occur in people, or whether the formulation reduces antibiotic use on working fish farms. MDPI

The carp study favored a modified peptide, not GHRP-6 itself, in its comparison of growth and immune measurements. Researchers conducted a four-week feeding experiment in common carp fry, meaning very young carp, comparing GHRP-6, a modified version called F5WAC, and a control group. They measured growth, feed conversion, meaning how efficiently feed was turned into body weight, hormone levels, and several measures of immune activity. DOI

F5WAC produced greater weight gain, a better feed conversion ratio, and a higher growth rate than GHRP-6 and the controls. It also raised growth hormone, a chemical messenger involved in growth, and increased several immune measurements. The activity of a gene involved in growth was higher as well. DOI

Cortisol, a hormone involved in the stress response, also rose with F5WAC. That matters when describing the findings: the experiment recorded changes across growth, immune activity, and a stress-related hormone, rather than a single measure of fish health. The limitation is that the abstract does not report an infection challenge or bacterial counts, so it does not show the same infection outcome as the tilapia experiment. MDPI+1

The two studies asked related questions, but they did not test the same outcome or identify the same peptide as the leading result. The tilapia experiment included infection and bacterial measurements, while the carp experiment compared the original peptide with a modified version over four weeks. Keeping those differences visible prevents the carp findings from being attributed to GHRP-6 alone. MDPI+1

Study	Design and sample	Main finding	Main limitation
Tilapia study	Oral formulation in young fish, with and without bacterial exposure	Greater growth and fewer bacteria after infection	Human effects were not tested. MDPI
Carp study	Four-week comparison in very young fish	F5WAC exceeded GHRP-6 on growth and immune measures	The abstract reports no infection outcome. DOI

This information is for research only. Not intended for human use.

The lower bacterial levels in tilapia provide a more direct measure of infection than changes in immune-related genes alone. The carp findings instead show that changing the peptide's structure can change the measured response within that experiment. Neither abstract establishes that higher immune measurements translate into longer survival or less antibiotic use in routine fish farming. MDPI+1

The tilapia findings extend an existing line of fish research rather than introducing the immune question for the first time. In 2021, a tilapia study examined GHRP-6 and reported increased activity of genes for antimicrobial molecules, substances that act against microbes, alongside greater antimicrobial activity. Its reported result therefore pointed toward changes in the fish's own defenses. MDPI+1

The 2026 tilapia study adds measurements of bacterial levels inside infected fish and digestive enzyme activity after infection. Those outcomes broaden the earlier focus on antimicrobial defenses by including what happened during a bacterial challenge. The limitation is that the supplied information does not support a numerical comparison of the size of the effects between the two studies. MDPI+1

Read in order, the 2021 and 2026 tilapia findings lean toward an effect on immune-related activity in this fish model. The carp study adds evidence that a related peptide can affect growth and immune measurements in another fish species. It does not establish that GHRP-6 and F5WAC are interchangeable, because F5WAC performed differently from GHRP-6 in the direct comparison. MDPI+2

Human research on GHRP-6 has tested different questions, including growth hormone release and recovery after stroke. In a 2002 diagnostic study, researchers compared hormone responses in adults to assess whether GHRP-6 could help identify growth hormone deficiency, meaning insufficient release of that hormone. The measured outcome was hormone release, not resistance to bacterial infection. Bioscientifica+2

The stroke studies moved beyond hormone testing, but they combined GHRP-6 with another compound rather than testing it alone. A 2024 early randomized trial, in which participants were assigned to groups by chance, reported trends toward better function after a stroke caused by blocked blood flow to the brain. The limitation is that a combination study cannot establish which effects came from GHRP-6 alone. Frontiers+1

In 2026, a larger randomized stroke trial missed its main outcome targets overall. A subgroup of patients with severe stroke had less disability at six months and lower mortality, but that finding sat within a trial whose main overall comparison did not meet its targets. These human results address recovery after stroke, not the immune or digestive outcomes selected in the new fish studies. MDPI+2

The new studies leave open whether lower bacterial levels or higher immune measurements lead to better long-term survival in fish farms. The supplied abstracts also do not establish an actual reduction in antibiotic use, despite that being part of the research motivation. For human research, the central gap remains translation: neither fish experiment establishes an immune benefit, an infection benefit, or a safety profile in people. MDPI+1